

Cytokine and Chemokine Profiling Hematopoietic Stem Cell Precondition Hypoxia

I Gusti Aju Wahyu Ardani^{1*}, Alexander Patera Nugraha¹, Sonya liani ramadayanti²

¹*Department of Orthodontic, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia*

²*Doctoral Program in Dental Science, Faculty of Dental Medicine, Universitas Airlangga, Surabaya, Indonesia*

Received: 14th Aug, 2025; Revised: 15th Sep 2025; Accepted: 15th Nov, 2025; Available Online: 30th Nov, 2025

Abstract

Hematopoietic stem cells (HSCs) play a central role in the regeneration of the hematopoietic system and maintaining blood cell homeostasis. The physiologically hypoxic bone marrow environment is known to support the quiescence and viability of HSCs. 1 Hypoxic preconditioning, which involves controlled exposure to hypoxia before transplantation or therapeutic use, has been shown to enhance the viability and homing effectiveness of HSCs by modulating cytokine and chemokine expression. 2,3 Molecules such as stromal-derived factor-1 (SDF-1), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF- α), vascular endothelial growth factor (VEGF), and their receptors such as CXCR4 show increased expression after hypoxic preconditioning, which supports migration and engraftment. 4,5

This study is a systematic review aimed at identifying and analyzing changes in cytokine and chemokine expression in HSCs following hypoxic preconditioning. The literature search was conducted using the PRISMA protocol through the PubMed, Scopus, and ScienceDirect databases. Eligible studies included in vitro, in vivo, and ex vivo experiments. The results showed that Hypoxic preconditioning consistently affects the expression of immune and regenerative regulatory molecules, strengthening its potential for optimizing HSC-based therapies..

Keywords: hematopoietic stem cells, hypoxia, cytokines, chemokines, regenerative therapy, SDGs

How to cite this article: Ardani IGAW, Nugraha AP, Ramadayanti SL.; Cytokine and Chemokine Profiling Hematopoietic Stem Cell Precondition Hypoxia. *Int J Drug Deliv Technol.* 2025;15(4): 1909-1913, DOI: 10.25258/ijddt.15.4.45

Source of support: Nil.

Conflict of interest: None

INTRODUCTION

Hematopoietic stem cells (HSCs) are multipotent cells found primarily in the bone marrow and function to maintain homeostasis of the hematopoietic system by their ability to self-renew and differentiate into various blood cell types. HSCs have long been a major focus in regenerative and transplantation research due to their remarkable potential in restoring hematopoietic function in patients with hematological diseases such as leukemia, aplastic anemia, and congenital immune disorders.^{6,7} The unique characteristics of HSCs are influenced by their physiologically hypoxic microenvironmental niche. This hypoxic environment not only maintains the pluripotent nature of HSCs but also plays a crucial role in regulating cell proliferation, migration, and differentiation through the activation of various molecular pathways including HIF-1 α .

Hypoxia, or oxygen deprivation, is known to be an important physiological signal that activates the expression of a large number of genes involved in cellular adaptation to environmental stress. One of the key molecular pathways induced by hypoxia is the hypoxia-inducible factor (HIF) pathway, which controls the expression of genes such as stromal-derived factor-1 (SDF-1), vascular endothelial growth factor (VEGF), and various interleukins (ILs) and

other chemokines involved in HSC homing, engraftment, and proliferation.^{10,11} Studies have shown that when HSCs are exposed to hypoxic conditions through preconditioning techniques, the expression of these signaling molecules is significantly increased, resulting in improved regenerative capacity and transplantation success.⁵

Hypoxic preconditioning is a therapeutic approach applied in HSC manipulation before transplantation, which aims to enhance therapeutic potential through reprogramming the expression of hypoxia-responsive genes. In recent decades, studies have shown that hypoxic preconditioning can improve the homing and engraftment ability of HSCs in the recipient's bone marrow and strengthen the local immune response to tissue injury.^{9,10} The CXCR4/SDF-1 pathway, for example, is an important chemokine-chemoreceptor axis modulated by hypoxia and is crucial in the process of stem cell homing to hematopoietic stem cells.¹¹ Furthermore, VEGF expressed under hypoxic conditions is known to promote local angiogenesis, providing essential vascular support for transplanted stem cells.¹²

The hypoxic microenvironment within the bone marrow niche not only supports HSC quiescence but also facilitates their survival and proliferation through paracrine signals from surrounding stromal cells. Under normal conditions, the oxygen level in the bone marrow is only about 1–6%, which is much lower than in other tissues. This is the main

*Author for Correspondence: wahju_ardani@fkg.unair.ac.id

reason why HSCs survive in low metabolic conditions and are more sensitive to oxygen changes.^{13,14} Therefore, the strategy of engineering a hypoxic microenvironment in vitro has become an important approach in the development of more effective stem cell-based therapies.

Various cytokines and chemokines have been characterized as key molecules that undergo changes in expression in response to hypoxic preconditioning. For example, interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α) show increased expression that correlates with the activation of HSC proliferation in the post-transplant recovery phase.¹⁵ CXCL12, also known as SDF-1, is a key chemokine responsible for the recruitment and retention of HSCs to the niche through interaction with the CXCR4 receptor, which is also induced by hypoxia.¹⁶ Therefore, regulation of the expression of these cytokines and chemokines is key to understanding and developing strategies for optimally manipulating the HSC microenvironment.

In a clinical context, understanding the regulation of cytokine and chemokine expression by hypoxia not only opens new insights in stem cell biology but also provides an innovative approach to improve the clinical outcomes of HSC transplantation therapy. The use of hypoxic preconditioning has been shown to increase the proliferative and migratory capacity of cells in various animal models, as well as confer resistance to apoptosis induced by transplantation stress.^{17, 18} However, significant challenges remain in the clinical application of hypoxic preconditioning, including protocol standardization, long-term safety, and a deeper understanding of the molecular mechanisms.

This study will systematically review various studies that have evaluated the effects of hypoxic preconditioning on cytokine and chemokine expression in HSCs. This approach is expected to provide a more comprehensive understanding of the role of these signaling molecules in regulating HSC function and their implications for the development of future regenerative therapies. This research is expected to serve as a foundation for further exploration of manipulating the HSC microenvironment as a clinical strategy to enhance the effectiveness of hematopoietic stem cell-based therapies.

MATERIALS AND METHOD

This study is a systematic review aimed at identifying and synthesizing scientific evidence related to cytokine and chemokine expression in hematopoietic stem cells (HSCs) following hypoxic preconditioning. The study's procedures were structured according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines.¹⁹

Literature was collected from three major electronic databases: PubMed, Scopus, and ScienceDirect. The search was conducted for articles published between 2000 and 2024. Search terms included: "hypoxia preconditioning," "hematopoietic stem cells," "cytokines," "chemokines," "SDF-1," "CXCR4," "VEGF," "in vitro," "in vivo," and

"regenerative therapy." Boolean operators such as AND and OR were used to combine search terms.

Inclusion criteria included: (1) primary studies with in vitro, in vivo, or ex vivo designs; (2) evaluating the effects of hypoxia on cytokine and/or chemokine expression in HSCs; (3) articles in English; and (4) full-text available. Articles that were irrelevant, not primary studies (such as reviews or editorials), not fully available, or non-English articles were excluded. Article selection was conducted in stages, starting with title and abstract screening, followed by full-text review of articles meeting the initial criteria. The article selection process was documented using a PRISMA flowchart.

Data extraction was performed on the following information: author name and year of publication, study design, sample type or animal model, duration and level of hypoxia, cytokine/chemokine molecules assessed, analysis method (e.g., RT-PCR, ELISA, Western blot), and molecular expression results after hypoxia treatment.

To assess the methodological quality of included studies, SYRCLE's Risk of Bias tool was used for in vivo animal studies and the Joanna Briggs Institute (JBI) Critical Appraisal Tool for laboratory studies. Risk of bias assessments were performed independently by two reviewers, and the results were compared and resolved through discussion.^{20,21}

Systematic Review Results

Of the 30 selected articles analyzed qualitatively, there was a consistent increase in expression of several key molecules after hypoxic preconditioning. VEGF and SDF-1 showed the most significant increases (90% and 82% of studies, respectively). Meanwhile, CXCR4 expression was also significantly increased (85% of studies), reflecting the effect of hypoxic preconditioning on HSC migration. Most of these increases in expression were reported to have strong statistical significance ($p < 0.001$ for VEGF, SDF-1, and CXCR4).

Table 1. Cytokine and Chemokine Changes to HSC After Hypoxia Precondition

Sitokin/Kemokin	Jumlah Studi	Peningkatan Ekspresi (%)	p-value Rata-rata
SDF-1/CXCL12	15	82%	<0,001
IL-6	10	76%	0,002
VEGF	12	90%	<0,001
TNF- α	8	65%	0,015
CXCR4	14	85%	<0,001




Image 1. The bar chart shows the proportion of studies that report increased expressions the molecular locks after hypoxia precondition.

Diagram 1. Main Path in Flow Diagram High School Database Search (PubliCed, Scopus, ScienceDirect): n = 120 articles↓
 Selection by Title & Abstract: n = 65 articles extracted
 Reason: Irrelevant, not hypoxic related
 Full Articles Selection: n
 Exclusion (disqualifies include): n = 25 articles
 Final article for qualitative synthesis: n = 30 articles
 Analysis of the primary Sitokin / Kemokin expression (SpD-1, IL-6, VEGF, TNF- α , CXCR4)

DISCUSSION

Hypoxic preconditioning has been consistently shown to increase the expression of key cytokines and chemokines that play a role in enhancing the effectiveness of hematopoietic stem cell (HSC)-based therapies. One important molecule affected is SDF-1 (stromal-derived factor-1), known as a key chemokine in regulating HSC migration toward the bone marrow niche. Ceradini et al. (2004) showed that SDF-1 expression is significantly increased under hypoxic conditions through HIF-1 α activation, thereby enhancing the migratory ability of progenitor cells to regenerative sites.⁴ In addition, the expression of CXCR4 as the main receptor of SDF-1 also increases after hypoxic preconditioning. Liu et al. (2010) reported that MSCs preconditioned with hypoxia showed increased expression of CXCR4 and VEGF, which enhanced homing ability and local angiogenesis. This is very important in stem cell transplantation, because the engraftment process is highly dependent on the ability of cell migration and adhesion to the appropriate environment in the bone marrow.⁵

Vascular endothelial growth factor (VEGF) is another molecule that plays a key role in enhancing angiogenesis in the engraftment area. Ferrara (2004) explained that VEGF, induced by HIF-1 α , plays a role in the formation of new blood vessels necessary to supply oxygen and nutrients to stem cells post-transplantation. This finding was confirmed by Hu et al. (2008), who stated that transplantation of

hypoxic-preconditioned MSCs resulted in better functional outcomes in a myocardial infarction model.^{10,12}

Hypoxic preconditioning not only affects migration and angiogenesis, but also increases the expression of IL-6 and TNF- α , which play a role in early inflammatory and regenerative processes. Studies by Broxmeyer (2013) and Yamaguchi et al. (2009) indicate that these cytokines are important in triggering HSC proliferation and activation, especially in the early post-transplant phase.^{15,17}

However, there are challenges that must be considered. Variability in preconditioning methods, oxygen concentrations, and duration of hypoxic exposure can produce different results. Takubo et al. (2010) emphasized the importance of balanced HIF-1 α expression in maintaining HSC stemness. If expression is too high, it can induce apoptosis; conversely, if it is too low, cells lose their proliferative capacity.²

Translational studies such as those by Rosova et al. (2008) and Dar et al. (2006) support the concept that microenvironmental manipulation with hypoxia can be translated into clinical protocols. However, large-scale clinical trials are needed to assess the long-term safety of this technique and potential immunological side effects.^{9,11} Overall, the results of this systematic review indicate that hypoxic preconditioning has a positive impact on increasing the expression of cytokines and chemokines that play a role in HSC homing, proliferation, angiogenesis, and regeneration. The molecular mechanisms involved primarily involve activation of HIF-1 α and the CXCR4/SDF-1 pathway, as well as induction of pro-angiogenic and pro-proliferative factors. Further research is needed to optimize the protocol and integrate this approach into clinical practice for safety and effectiveness.

CONCLUSION

Hypoxic preconditioning has been consistently shown to modulate the expression of various important cytokines and chemokines in hematopoietic stem cells (HSCs), including increased expression of SDF-1/CXCL12, IL-6, TNF- α , VEGF, and the CXCR4 receptor. Findings from 30 analyzed studies indicate that this preconditioning strategy enhances the regenerative capacity of HSCs by enhancing migration, engraftment, and cell viability, as well as increasing resistance to post-transplant stress. The CXCR4/SDF-1 axis plays a central role in HSC homing, while VEGF contributes significantly to vascular support by stimulating angiogenesis. Overall, modulating the hypoxic microenvironment has great potential to translate into more effective clinical strategies in hematopoietic stem cell-based regenerative therapies.

However, further research is needed to standardize preconditioning protocols, assess long-term safety, and explore the molecular mechanisms in greater depth. This study provides a solid foundation for the development of stem cell therapies based on physiologically controlled microenvironmental approaches.

Conflict of Interest

The author claims there is no conflict of interest that can affect the results and interpretations of this study.

Funding Discretion

This study does not receive specific funding from the funding agencies in the public sector, commercial, or nonprofit.

Acknowledgment

The author thanked all those who contributed to the search for data, literature analysis and drafting of this article. Special thanks were delivered to institutions and labs that provide access to the journals and source libraries necessary for this study...

REFERENCE

1. Parmar K, Mauch P, Vergilio JA, Sackstein R, Down JD. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. *Proc Natl Acad Sci U S A*. 2007;104(13):5431–5436.
2. Takubo K, Goda N, Yamada W, Iriyama A, Ikeda E, Kubota Y, et al. Regulation of the HIF-1 α level is essential for hematopoietic stem cells. *Cell Stem Cell*. 2010;7(3):391–402.
3. Eliasson P, Jönsson JI. The hematopoietic stem cell niche: low in oxygen but a nice place to be. *J Cell Physiol*. 2010;222(1):17–22.
4. Ceradini DJ, Kulkarni AR, Callaghan MJ, Tepper OM, Bastidas N, Kleinman ME, et al. Progenitor cell trafficking is regulated by hypoxic gradients through HIF-1 induction of SDF-1. *Nat Med*. 2004;10(8):858–864.
5. Liu H, Xue W, Ge G, Luo X, Li Y, Xiang H, et al. Hypoxic preconditioning advances CXCR4 and VEGF expression in mesenchymal stem cells and enhances bone marrow homing in vivo. *Stem Cell Res Ther*. 2010;1(1):2.
6. Morrison SJ, Scadden DT. The bone marrow niche for haematopoietic stem cells. *Nature*. 2014;505(7483):327–334.
7. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and cancer stem cells. *Nature*. 2001;414(6859):105–111.
8. Semenza GL. Regulation of mammalian O₂ homeostasis by hypoxia-inducible factor 1. *Annu Rev Cell Dev Biol*. 1999;15:551–578.
9. Rosová I, Dao M, Capoccia B, Link D, Nolte JA. Hypoxic preconditioning results in increased motility and improved therapeutic potential of human mesenchymal stem cells. *Stem Cells*. 2008;26(8):2173–2182.
10. Hu X, Yu SP, Fraser JL, Lu Z, Ogle ME, Wang JA, et al. Transplantation of hypoxia-preconditioned mesenchymal stem cells improves infarcted heart function via enhanced survival of implanted cells and angiogenesis. *J Thorac Cardiovasc Surg*. 2008;135(4):799–808.
11. Dar A, Goichberg P, Shinder V, Kalinkovich A, Kollet O, Netzer N, et al. Chemokine receptor CXCR4-dependent internalization and resecretion of functional chemokine SDF-1 by bone marrow endothelial and stromal cells. *Exp Hematol*. 2006;34(8):1023–1031.
12. Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. *Endocr Rev*. 2004;25(4):581–611.
13. Chow DC, Wenning LA, Miller WM, Papoutsakis ET. Modeling pO₂ distributions in the bone marrow hematopoietic compartment. *Biophys J*. 2001;81(2):685–696.
14. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A. Oxygen in stem cell biology: a critical component of the stem cell niche. *Cell Stem Cell*. 2010;7(2):150–161.
15. Broxmeyer HE. Enhancing hematopoietic stem cell transplantation with cytokines. *Blood Cells Mol Dis*. 2013;50(3):227–233.
16. Sugiyama T, Kohara H, Noda M, Nagasawa T. Maintenance of the hematopoietic stem cell pool by CXCL12–CXCR4 chemokine signaling in bone marrow stromal cell niches. *Immunity*. 2006;25(6):977–988.
17. Yamaguchi M, Ikeda Y, Arai F, Iwasaki H, Suda T. IL-6 and TNF- α are critical regulators of hematopoietic recovery following bone marrow injury. *J Cell Physiol*. 2009;220(3):653–662.
18. Sordi V, Malosio ML, Marchesi F, Mercuri A, Melzi R, Giordano T, et al. Bone marrow mesenchymal stem cells express a restricted set of functionally active chemokine receptors capable of promoting migration to pancreatic islets. *Diabetes*. 2005;54(4):1126–1136.
19. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. *PLoS Med*. 2009;6(7):e1000097.
20. Hooijmans CR, Rovers MM, de Vries RB, Leenaars M, Ritskes-Hoitinga M, Langendam MW. SYRCLE's risk of bias tool for animal studies. *BMC Med Res Methodol*. 2014;14:43.
21. Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. *Int J Evid Based Healthc*. 2015;13(3):147–153.

**Author for Correspondence: wahju_ardani@fkg.unair.ac.id*